Prognosis of Failure Treatment of Amebic Liver Abscess
March 17, 2008 updated by: Universidad Autonoma de San Luis Potosí
Prognosis Factors of the Response After Medical Treatment of Amebic Liver Abscess
Amebic liver abscess is the most frequent extra-intestinal form of the amoebiasis; actually the factors for predicting failure in the medical treatment are not clear.
We conducted trial for determining the clinical value of paraclinical factor in this issue.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico DF, Mexico
- Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán".
-
San Luis Potosi, Mexico, 78210
- Faculty of Medicine, Universidad Autónoma de San Luis Potosí
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 80 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
sequential patients with clinical, ultrasonographic and serologic diagnosis (ELISA) of amebic liver abscess
Description
Inclusion Criteria:
- Clinical, ultrasonographic and serologic diagnosis (ELISA) of amebic liver abscess.
- Both genders
- Older 15 years
Exclusion Criteria:
- Clinically suspected piogenous liver abscess
- Positive hemoculture
- Negative ELISA for amoebic antigens
- Immunosupresion (HIV)
- Abdominal or biliary surgery antecedents
- Abdominal neoplasia antecedents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
1
Response to medical treatment
|
|
2
Failure to medical treatment (surgery or percutaneous resolution)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Failure of medical treatment
Time Frame: Day 4
|
Day 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Martín Sánchez-Aguilar 1, MSc, 1. Department of Experimental Surgery, Faculty of Medicine, Universidad Autónoma de San Luis Potosí
- Study Director: Onofre Morán-Mendoza, PhD, Department of Clinical Epidemiology, Faculty of Medicine, Universidad Autónoma de San Luis Potosí
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 1999
Primary Completion (Actual)
April 1, 2000
Study Completion (Actual)
April 1, 2000
Study Registration Dates
First Submitted
March 12, 2008
First Submitted That Met QC Criteria
March 17, 2008
First Posted (Estimate)
March 24, 2008
Study Record Updates
Last Update Posted (Estimate)
March 24, 2008
Last Update Submitted That Met QC Criteria
March 17, 2008
Last Verified
March 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PFP-ALA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.